1. Home
  2. ENTA vs CGC Comparison

ENTA vs CGC Comparison

Compare ENTA & CGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$13.30

Market Cap

378.0M

Sector

Health Care

ML Signal

HOLD

Logo Canopy Growth Corporation

CGC

Canopy Growth Corporation

HOLD

Current Price

$1.02

Market Cap

401.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTA
CGC
Founded
1995
N/A
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Pharmaceuticals and Biotechnology
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
378.0M
401.0M
IPO Year
2012
2023

Fundamental Metrics

Financial Performance
Metric
ENTA
CGC
Price
$13.30
$1.02
Analyst Decision
Strong Buy
Hold
Analyst Count
5
1
Target Price
$20.40
N/A
AVG Volume (30 Days)
156.5K
2.9M
Earning Date
05-11-2026
05-29-2026
Dividend Yield
N/A
N/A
EPS Growth
29.93
84.17
EPS
N/A
N/A
Revenue
$102,814,000.00
$12,759,000.00
Revenue This Year
$7.76
$8.27
Revenue Next Year
N/A
$15.68
P/E Ratio
N/A
N/A
Revenue Growth
16.48
N/A
52 Week Low
$7.05
$0.84
52 Week High
$17.15
$2.38

Technical Indicators

Market Signals
Indicator
ENTA
CGC
Relative Strength Index (RSI) 51.08 60.45
Support Level $12.95 $1.01
Resistance Level $13.98 $1.08
Average True Range (ATR) 0.58 0.04
MACD 0.01 0.01
Stochastic Oscillator 61.40 84.62

Price Performance

Historical Comparison
ENTA
CGC

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

About CGC Canopy Growth Corporation

Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.

Share on Social Networks: